L-丝氨酸治疗遗传性感觉自主神经病1型的随机试验
这项随机、安慰剂对照、平行组试验纳入18例有症状的HSAN1患者,随机接受L-丝氨酸(400 mg/kg/天)或安慰剂治疗1年,随后全部接受L-丝氨酸治疗1年。主要终点CMTNS在L-丝氨酸组较安慰剂组改善(-1.5单位,95%CI -2.8至-0.1,p=0.03),脱氧鞘氨醇水平下降(59% vs 11%升高,p<0.001),无严重不良事件。
要点
- L-丝氨酸400 mg/kg/天治疗1年可改善HSAN1患者CMTNS评分。
- L-丝氨酸治疗使脱氧鞘氨醇水平下降59%,安慰剂组升高11%。
- L-丝氨酸未出现相关严重不良事件,安全性良好。
核心结论
- 高剂量口服L-丝氨酸补充在HSAN1患者中安全性良好,可能有效延缓疾病进展。
- 研究提供I类证据表明高剂量口服L-丝氨酸显著延缓HSAN1疾病进展。
研究设计与样本
- 随机、安慰剂对照、平行组试验,设开放标签延长期,纳入18例18-70岁有症状HSAN1患者。
- 患者随机接受L-丝氨酸(400 mg/kg/天)或安慰剂治疗1年,第二年全部接受L-丝氨酸治疗。
- 主要终点为CMTNS评分,次要终点包括血浆鞘脂水平、表皮神经纤维密度、电生理指标、患者报告指标和不良事件。
主要发现
- 治疗1年后,L-丝氨酸组CMTNS较安慰剂组改善(-1.5单位,95%CI -2.8至-0.1,p=0.03)。
- 第二年治疗期间继续改善趋势(-0.77,95%CI -1.67至0.13,p=0.09)。
- 脱氧鞘氨醇水平在L-丝氨酸组下降59%,安慰剂组升高11%(p<0.001)。
- 未发生与L-丝氨酸相关的严重不良事件。
关键数值与推荐
- L-丝氨酸剂量为400 mg/kg/天,口服。
- 主要终点CMTNS组间差异为-1.5单位(95%CI -2.8至-0.1,p=0.03)。
- 脱氧鞘氨醇水平变化:L-丝氨酸组下降59%,安慰剂组升高11%(p<0.001)。
临床怎么用
- 对于有症状的HSAN1患者,可考虑高剂量口服L-丝氨酸治疗以延缓疾病进展。
- 治疗期间可监测血浆脱氧鞘氨醇水平作为药效学指标。
- L-丝氨酸治疗安全性良好,但仍需关注不良事件。
局限性
- 样本量较小(纳入18例,完成16例)。
- 第二年开放标签延长期改善趋势未达统计学显著性(p=0.09)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of l-serine in humans with hereditary sensory autonomic neuropathy type I (HSAN1). METHODS: In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients aged 18-70 years with symptomatic HSAN1 were randomized to l-serine (400 mg/kg/day) or placebo for 1 year. All participants received l-serine during the second year. The primary outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS). Secondary outcomes included plasma sphingolipid levels, epidermal nerve fiber density, electrophysiologic measurements, patient-reported measures, and adverse events. RESULTS: Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom completed the study. After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, p = 0.03), with evidence of continued improvement in the second year of treatment (-0.77, 95% CI -1.67 to 0.13, p = 0.09). Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001). There were no serious adverse effects related to l-serine. CONCLUSION: High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression. CLINICALTRIALSGOV IDENTIFIER: NCT01733407. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.
引用
- Fridman V, Suriyanarayanan S, Novak P, et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology. 2019. PMID: 30626650. doi:10.1212/WNL.0000000000006811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。